💉 A celiac drug finally in people
Hey readers! Most celiac news lives in mouse models and petri dishes, so it's worth pausing when an actual investigational drug reaches an actual patient. This issue leads with the UK's first participant in the ANB033 trial, then points you toward concrete places to go: a new adult celiac center taking patients, updated testing guidelines you can bring to your clinician, and a gluten-threshold study that should change how you think about cross-contact.
"I hope it helps millions": Belfast woman first in UK to trial new coeliac disease drug covers Caroline Clarke, who became the first UK patient recruited into the early-phase international ANB033-101 trial at the Ulster Hospital. The South Eastern Trust's Gastroenterology and Research Team is running the local arm of a study that will include about 60 participants worldwide.
- Belfast Live
What matters here is that this is real, in-human work on a condition where the only management remains a strict gluten-free diet. Participants receive three doses of an investigational medicine or placebo by subcutaneous injection, with blood tests and endoscopies before and after to measure changes in the intestinal lining. Clarke was diagnosed in 2019 after years of unexplained symptoms, a story many of you will recognize.
Dr Grant Caddy, Consultant Gastroenterologist, framed it honestly: "Obviously this is an early-stage trial and it may take time before any potential treatment becomes available to patients. But this is an important stepping stone in the direction of trying to improve care for people living with coeliac disease."
Temper expectations accordingly. An early-phase trial with roughly 60 people is about safety and signal, not an imminent prescription. Still, for anyone who stays symptomatic despite careful eating, seeing a drug candidate move into patients is the kind of progress that has been missing for a long time.
🏥 A place to actually go: new adult celiac center
UC Health opens first adult celiac disease center in partnership with Cincinnati Children's reports that UC Health opened Southern Ohio's first dedicated adult celiac center at its Montgomery Building in Cincinnati on Sept. 10, 2026, built with Cincinnati Children's Celiac Disease Center.
- newsrecord.org
If you parent a child with celiac, the transition out of pediatric care is a real cliff, and this program is designed to catch patients as they age out. Director Amanda Cartee says there was previously no comparable adult "home" of this kind in the country.
"The patients that are being treated at the children's celiac disease center now have a home to go to when they're an adult," Cartee said.
The center is focused on treatment, testing, and managing ongoing symptoms and complications right now, not research, though Cartee expects research to follow. A worthwhile referral to keep on file.
🔬 Tests and thresholds worth bringing to your clinician
Two items that directly inform how you get diagnosed and how carefully you need to eat.
Blood tests rules out celiac disease during gluten-free diet describes an experimental blood test that identifies celiac disease even in people already avoiding gluten, by targeting gluten-reactive immune cells rather than the fading antibody response standard tests rely on. In a study spanning 62 celiac patients on gluten-free diets, 19 non-celiac people on gluten-free diets, 10 celiac patients eating gluten, and 52 healthy people, the test was 96% accurate at distinguishing celiac patients from non-celiac people who were still gluten-free.
- Times of Malta
"Many persons with gluten sensitivity go gluten-free without consulting their clinician for exclusion of celiac disease," said lead author Vikas K. Sarna of Oslo University Hospital, who stressed the test "is still not available for commercial use."
That "already gone gluten-free before testing" problem is exactly why diagnosis is so hard to nail down after the fact. For now, the practical takeaway stands: finish testing before you cut gluten.
How Much Gluten Is Too Much? New Study Finds Celiac Immune Reaction at Just 3 mg is the one to read if you worry about cross-contact. In a randomized, double-blind Australian trial published in Gastroenterology, 17% of participants showed an IL-2 immune reaction at just 3 mg of gluten, and symptoms did not reliably track with exposure at these low doses.
- Glutendtrotters
"This is the first time we've been able to demonstrate, with certainty, that even very small gluten exposures can activate the immune system in people with coeliac disease," said Dr. Daveson in the Wesley Research Institute's announcement.
The honest caveat from the authors: feeling fine after a meal doesn't guarantee you weren't exposed, and feeling unwell doesn't confirm you were. This is the evidence behind caring about shared toasters and cutting boards.
BSG Updates Coeliac Disease Testing Standards: The British Society of Gastroenterology released updated celiac testing guidelines in July 2026, replacing the 2014 version with a flexible, risk-stratified model. IgA tissue transglutaminase (tTG) remains first-line, and patients still must be eating gluten before testing. Worth knowing if you're in the UK system. - Evans Fam
Celiac Disease Is More Common Than Thought: A Gastroenterology study puts celiac at 1 in 120 people worldwide by biopsy and 1 in 70 seropositive, with 41% of confirmed cases having no symptoms. Experts argue it's still underdiagnosed, partly because people go gluten-free before getting tested. - iFitness Mag
🧫 The science shaping tomorrow's treatments
These are earlier-stage findings, mostly in cells and mice, but they explain where future "gatekeeper" drugs might aim.
Celiac Disease: New Research Identifies How Intestinal Cells Trigger Immune Responses to Gluten reports McMaster University work (led by Dr. Elena Verdu and Dr. Tohid Didar) suggesting intestinal epithelial cells aren't passive barriers but can present gluten fragments to T-cells and recruit intraepithelial lymphocytes.
- Santenews
The findings suggest that epithelial cells "appear capable of directly presenting gluten fragments to T-cells."
If that holds up in human trials, it points toward drugs that block the gluten-epithelial interaction. Replication in people is still the open question.
Gut Bacterium Linked to Gluten Sensitivity: A Gut Microbes mouse study found gluten caused intestinal damage only when secretory IgA was missing and a single species, Streptococcus lutetiensis, was present, which may help explain why IgA deficiency raises celiac risk. Early, single-lab, and mouse-based. - Biomesci
Beyond HLA-DQ2/DQ8: More Genes Linked to Celiac Disease: Researchers screened 51 non-HLA genes in 376 celiac cases and 736 controls and found 18 variants associated with celiac. Nothing changes at diagnosis yet, and the findings need replication in other populations. - Glutendtrotters
Grape seed compound reduced gluten-linked intestinal stress in mice: Grape seed procyanidins eased gliadin-induced epithelial stress in cells and mice via the ATF4 pathway. Note clearly: this was not tested in people and is no evidence that grape seed extract treats celiac disease. - Vinetur
🍽️ One practical note for living gluten-free
Given the 3 mg threshold findings above, eating out safely is a real skill. When you need to find vetted gluten-free restaurants, reviews, or travel options, the community-driven Find Me Gluten Free site and app is a genuinely useful tool. We're not sponsored by them; it just earns its place on a phone.
That's the issue. The headline is simple: a celiac drug candidate is now in people, even if it's early and modest in scale. Everything else here gives you somewhere concrete to point your attention this week.